Total Payments
$21,786
2024 Payments
$18.09
Companies
9
Transactions
29
Medicare Patients
1,189
Medicare Billing
$197,064
Payment Breakdown by Category
Other$16,135 (74.1%)
Consulting$3,360 (15.4%)
Travel$1,704 (7.8%)
Food & Beverage$522.75 (2.4%)
Education$64.45 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,135 | 5 | 74.1% |
| Consulting Fee | $3,360 | 6 | 15.4% |
| Travel and Lodging | $1,704 | 6 | 7.8% |
| Food and Beverage | $522.75 | 8 | 2.4% |
| Education | $64.45 | 4 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19,283 | 20 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $1,995 | 2 | $0 (2017) |
| Amgen Inc. | $400.00 | 1 | $0 (2017) |
| EMD Serono, Inc. | $26.58 | 1 | $0 (2023) |
| Myovant Sciences Inc. | $23.93 | 1 | $0 (2021) |
| Merck Sharp & Dohme LLC | $18.09 | 1 | $0 (2024) |
| Genentech USA, Inc. | $17.82 | 1 | $0 (2018) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
| Celgene Corporation | $10.51 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18.09 | 1 | Merck Sharp & Dohme LLC ($18.09) |
| 2023 | $26.58 | 1 | EMD Serono, Inc. ($26.58) |
| 2021 | $35.85 | 2 | Myovant Sciences Inc. ($23.93) |
| 2018 | $10,964 | 16 | E.R. Squibb & Sons, L.L.C. ($10,935) |
| 2017 | $10,742 | 9 | E.R. Squibb & Sons, L.L.C. ($8,347) |
All Payment Transactions
29 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $26.58 | General |
| Category: Neurology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 04/01/2021 | Myovant Sciences Inc. | ORGOVYX (Drug) | Education | In-kind items and services | $23.93 | General |
| Category: HORMONE THERAPY | ||||||
| 12/27/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,050.00 | General |
| Category: Oncology | ||||||
| 09/10/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $124.30 | General |
| Category: Oncology | ||||||
| 09/10/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $99.21 | General |
| Category: Oncology | ||||||
| 07/31/2018 | Celgene Corporation | Revlimid (Drug) | Education | In-kind items and services | $10.51 | General |
| Category: Hematology / Oncology | ||||||
| 07/24/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| Category: Oncology | ||||||
| 07/16/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $563.10 | General |
| Category: Oncology | ||||||
| 07/16/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $486.86 | General |
| Category: Oncology | ||||||
| 07/16/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $84.00 | General |
| Category: Oncology | ||||||
| 05/14/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Oncology | ||||||
| 05/01/2018 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: BioOncology | ||||||
| 01/30/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Oncology | ||||||
| 01/18/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $83.07 | General |
| Category: Oncology | ||||||
| 01/18/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $33.35 | General |
| Category: Oncology | ||||||
| 01/11/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $92.20 | General |
| Category: Oncology | ||||||
| 01/11/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $9.35 | General |
| Category: Oncology | ||||||
| 01/02/2018 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Oncology | ||||||
| 12/15/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,050.00 | General |
| Category: Oncology | ||||||
| 12/11/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $379.80 | General |
| Category: Oncology | ||||||
| 08/29/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,325.00 | General |
| Category: Oncology | ||||||
| 08/21/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $92.35 | General |
| Category: Oncology | ||||||
| 08/02/2017 | Amgen Inc. | Kyprolis (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 325 | 565 | $199,214 | $58,320 |
| 2022 | 7 | 284 | 518 | $133,396 | $43,351 |
| 2021 | 7 | 292 | 576 | $144,456 | $50,147 |
| 2020 | 4 | 288 | 570 | $139,330 | $45,245 |
Total Patients
1,189
Total Services
2,229
Medicare Billing
$197,064
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 125 | 313 | $120,497 | $36,988 | 30.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 114 | 163 | $38,969 | $10,158 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 41 | 41 | $21,223 | $6,047 | 28.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 21 | $11,486 | $3,117 | 27.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $4,902 | $1,468 | 29.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 14 | $2,138 | $542.35 | 25.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 150 | 352 | $76,992 | $25,861 | 33.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 37 | 51 | $15,750 | $5,545 | 35.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 33 | 33 | $15,430 | $4,472 | 29.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $7,868 | $2,365 | 30.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 25 | $7,341 | $2,173 | 29.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $6,442 | $1,731 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 25 | $3,573 | $1,204 | 33.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 152 | 384 | $82,214 | $28,287 | 34.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 42 | 76 | $22,982 | $9,118 | 39.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 33 | 33 | $15,144 | $5,264 | 34.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 17 | 31 | $8,762 | $2,616 | 29.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 11 | $6,039 | $1,893 | 31.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $5,974 | $1,886 | 31.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 20 | 24 | $3,341 | $1,084 | 32.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 152 | 331 | $65,597 | $20,240 | 30.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 78 | 180 | $48,476 | $16,359 | 33.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 44 | 44 | $18,237 | $6,170 | 33.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 14 | 15 | $7,021 | $2,476 | 35.3% |
About Dr. Eric Dean, M.D
Dr. Eric Dean, M.D is a Medical Oncology healthcare provider based in Kirkland, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1366632671.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Dean, M.D has received a total of $21,786 in payments from pharmaceutical and medical device companies, with $18.09 received in 2024. These payments were reported across 29 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($16,135).
As a Medicare-enrolled provider, Dean has provided services to 1,189 Medicare beneficiaries, totaling 2,229 services with total Medicare billing of $197,064. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Kirkland, WA
- Active Since 08/01/2007
- Last Updated 01/26/2016
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1366632671
Products in Payments
- OPDIVO (Biological) $18,783
- IMFINZI (Drug) $1,995
- EMPLICITI (Biological) $500.00
- Kyprolis (Biological) $400.00
- MAVENCLAD (Drug) $26.58
- ORGOVYX (Drug) $23.93
- WELIREG (Drug) $18.09
- TECENTRIQ (Biological) $17.82
- Revlimid (Drug) $10.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.